Abstract

Triple-negative breast cancer (TNBC) patients have a poor prognosis and few treatment options. Mouse models of TNBC are important for development of new therapies, however, few mouse models represent the complexity of TNBC. Here, we develop a female TNBC murine model by mimicking two common TNBC mutations with high co-occurrence: amplification of the oncogene MYC and deletion of the tumor suppressor PTEN. This Myc;Ptenfl model develops heterogeneous triple-negative mammary tumors that display histological and molecular features commonly found in human TNBC. Our research involves deep molecular and spatial analyses on Myc;Ptenfl tumors including bulk and single-cell RNA-sequencing, and multiplex tissue-imaging. Through comparison with human TNBC, we demonstrate that this genetic mouse model develops mammary tumors with differential survival and therapeutic responses that closely resemble the inter- and intra-tumoral and microenvironmental heterogeneity of human TNBC, providing a pre-clinical tool for assessing the spectrum of patient TNBC biology and drug response.

Few mouse models recapitulate the complexity of triple negative breast cancer (TNBC). Here, the authors develop and characterise a TNBC mouse model harbouring two common TNBC mutations: amplification of the oncogene MYC and deletion of the tumour suppressor PTEN.

Details

Title
MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer
Author
Doha, Zinab O. 1 ; Wang, Xiaoyan 2 ; Calistri, Nicholas L. 3   VIAFID ORCID Logo  ; Eng, Jennifer 4   VIAFID ORCID Logo  ; Daniel, Colin J. 2 ; Ternes, Luke 3 ; Kim, Eun Na 3 ; Pelz, Carl 5 ; Munks, Michael 6 ; Betts, Courtney 7 ; Kwon, Sunjong 8 ; Bucher, Elmar 8 ; Li, Xi 9 ; Waugh, Trent 2 ; Tatarova, Zuzana 8 ; Blumberg, Dylan 8 ; Ko, Aaron 10 ; Kirchberger, Nell 7 ; Pietenpol, Jennifer A. 11 ; Sanders, Melinda E. 12 ; Langer, Ellen M. 2   VIAFID ORCID Logo  ; Dai, Mu-Shui 2   VIAFID ORCID Logo  ; Mills, Gordon 13   VIAFID ORCID Logo  ; Chin, Koei 14   VIAFID ORCID Logo  ; Chang, Young Hwan 15   VIAFID ORCID Logo  ; Coussens, Lisa M. 16   VIAFID ORCID Logo  ; Gray, Joe W. 14   VIAFID ORCID Logo  ; Heiser, Laura M. 17   VIAFID ORCID Logo  ; Sears, Rosalie C. 18   VIAFID ORCID Logo 

 Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Taibah University, Department of medical laboratory technology, Al-Madinah al-Munawwarah, Saudi Arabia (GRID:grid.412892.4) (ISNI:0000 0004 1754 9358) 
 Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Oregon Health and Science University, Department of Molecular Microbiology and Immunology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 Oregon Health and Science University, Department of Cell, Developmental & Cancer Biology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
 Division of Oncologic Sciences, Oregon Health and Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
10  Oregon Health and Science University, Department of Molecular Microbiology and Immunology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
11  Vanderbilt University Medical Center, Department of Biochemistry, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916) 
12  Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916); Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology, Nashville, USA (GRID:grid.412807.8) (ISNI:0000 0004 1936 9916) 
13  Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Division of Oncologic Sciences, Oregon Health and Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
14  Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
15  Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
16  Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Oregon Health and Science University, Department of Cell, Developmental & Cancer Biology, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
17  Oregon Health & Science University, Department of Biomedical Engineering, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); OHSU Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
18  Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690); Knight Cancer Institute, Oregon Health & Science University, Portland, USA (GRID:grid.5288.7) (ISNI:0000 0000 9758 5690) 
Pages
5665
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2864389760
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.